<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/360bbb–4a" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/360bbb–4a/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/360bbb–4a/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_360bbb_4a"><akn:num>360bbb–4a</akn:num><akn:heading>Priority review to encourage treatments for agents that present national security threats</akn:heading><akn:content><akn:p>§ 360bbb–4a. Priority review to encourage treatments for agents that present national security threats(a) DefinitionsIn this section:(1) Human drug applicationThe term “human drug application” has the meaning given such term in section 379g(1) of this title.


(2) Priority reviewThe term “priority review”, with respect to a human drug application, means review and action by the Secretary on such application not later than 6 months after receipt by the Secretary of such application, as described in the Manual of Policies and Procedures in the Food and Drug Administration and goals identified in the letters described in section 101(b) of the Food and Drug Administration Safety and Innovation Act.


(3) Priority review voucherThe term “priority review voucher” means a voucher issued by the Secretary to the sponsor of a material threat medical countermeasure application that entitles the holder of such voucher to priority review of a single human drug application submitted under section 355(b)(1) of this title or section 351(a) of the Public Health Service Act [42 U.S.C. 262(a)] after the date of approval of the material threat medical countermeasure application.


(4) Material threat medical countermeasure applicationThe term “material threat medical countermeasure application” means an application that—(A) is a human drug application for a drug intended for use—(i) to prevent, or treat harm from a biological, chemical, radiological, or nuclear agent identified as a material threat under section 319F–2(c)(2)(A)(ii) of the Public Health Service Act [42 U.S.C. 247d–6b(c)(2)(A)(ii)]; or

(ii) to mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, or biological product against such agent; and


(B) the Secretary determines eligible for priority review;

(C) is approved after December 13, 2016; and

(D) is for—(i) a human drug, no active moiety (as defined by the Secretary in se</akn:p></akn:content><akn:subsection eId="subsec_360bbb_4a_a"><akn:num>(a)</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>(a) Definitions In this section:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4a_b"><akn:num>(b)</akn:num><akn:heading>Priority review voucher</akn:heading><akn:content><akn:p>(b) Priority review voucher</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4a_c"><akn:num>(c)</akn:num><akn:heading>Priority review user fee</akn:heading><akn:content><akn:p>(c) Priority review user fee</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4a_d"><akn:num>(d)</akn:num><akn:heading>Notice of issuance of voucher and approval of products under voucher</akn:heading><akn:content><akn:p>(d) Notice of issuance of voucher and approval of products under voucher The Secretary shall publish a notice in the Federal Register and on the Internet website of the Food and Drug Administration not later than 30 calendar days after the occurrence of each of the following:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4a_e"><akn:num>(e)</akn:num><akn:heading>Eligibility for other programs</akn:heading><akn:content><akn:p>(e) Eligibility for other programs Nothing in this section precludes a sponsor who seeks a priority review voucher under this section from participating in any other incentive program, including under this chapter, except that no sponsor of a material threat medical countermeasure application may receive more than one priority review voucher issued under any section of this chapter with respect to such drug.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4a_f"><akn:num>(f)</akn:num><akn:heading>Relation to other provisions</akn:heading><akn:content><akn:p>(f) Relation to other provisions The provisions of this section shall supplement, not supplant, any other provisions of this chapter or the Public Health Service Act [42 U.S.C. 201 et seq.] that encourage the development of medical countermeasures.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360bbb_4a_g"><akn:num>(g)</akn:num><akn:heading>Sunset</akn:heading><akn:content><akn:p>(g) Sunset The Secretary may not award any priority review vouchers under subsection (b) after October 1, 2023.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>